A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
The US Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...